Full-Time

Associate Director, Experience Design

Suite Lead

Updated on 9/16/2026

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

No salary listed

Pennsylvania, USA

Remote

Remote within Pennsylvania, with 20–30% travel required.

Bachelor's, Master's, MBA

Category
Product & Experience Design

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • Deep subject matter expertise in customer journey mapping, service design, and customer experience/user experience frameworks, with the ability to design journeys across complex, multi-channel environments.
  • Strong analytical and problem-solving skills to identify experience-level friction and root causes and translate insights into structural design improvements.
  • Ability to design reusable, scalable experience patterns for orchestration and engagement teams.
  • Understanding of omnichannel execution and orchestration models.
  • Ability to interpret customer feedback and performance signals to inform experience design.
  • Enterprise design leadership skills, including influencing through standards, principles, and clarity rather than direct execution ownership.
  • Ability to lead and influence without direct authority, navigate ambiguity, and drive alignment across cross-functional stakeholders.
  • Experience leading and developing a high-performing team, including resource planning, performance management, and talent development.
  • Ability to understand customers' end-to-end experiences and use that understanding for go-to-market strategic, tactical, and measurement decisions.
  • Ability to understand how value is created financially, operationally, and for customers, and use that insight to make decisions that drive business outcomes.
  • Ability to craft purposeful narratives that explain change, inspire action, and align people around a shared direction.
  • Ability to understand upstream and downstream effects across the organization and identify patterns and interdependencies.
  • Ability to seek, absorb, and apply new insights and feedback to real situations.
  • Bachelor's degree in business, healthcare, technology, or a related field.
  • At least 8 years of experience in customer or user experience design within a pharmaceutical organization.
  • At least 6 years of experience leading people, including managing and developing high-performing teams and driving accountability across functions.
Responsibilities
  • Define and own enterprise customer journey frameworks, including experience principles, journey stages, and intended experience outcomes across channels.
  • Lead customer experience and user experience design at the journey level, translating customer needs and insights into clear experience outcomes.
  • Identify systemic customer friction points across journeys and define experiences to address them.
  • Create reusable experience designs, patterns, and standards that can be consistently applied across brands, channels, and engagement teams.
  • Translate customer feedback and performance insights into experience design guidance and embed learnings into future journey design.
  • Partner with brand and franchise teams to ensure enterprise journey designs support brand strategy while maintaining cross-brand consistency.
  • Assess new business contexts across brands and geographies to align on critical experience priorities.
  • Partner with the Omnichannel Orchestration team to hand off journey designs, experience principles, and success criteria and support their translation into experience blueprints.
  • Collaborate with Performance Analytics & Optimization and Customer Analytics & Insights teams to integrate customer feedback, voice-of-customer data, net promoter score data, and insights on customer barriers and opportunities into journey design.
  • Improve the simplicity, intuitiveness, and effectiveness of processes and tools for external customers and critical internal user groups.
  • Serve as the voice of experience design in cross-functional and team planning discussions, influencing priorities and incorporating customer needs, dependencies, and constraints.
  • Build credibility, convene stakeholders, and shape solutions in dynamic stakeholder environments.
  • Travel 20–30% as required.
Desired Qualifications
  • Advanced degree, such as a Master of Business Administration or relevant graduate degree.
  • Experience in healthcare, pharmaceutical, or other highly regulated industries.
  • Experience working in rare disease or specialty brands, with a strong understanding of unique stakeholder dynamics.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.